Suppr超能文献

载有更昔洛韦的可生物降解聚乳酸-羟基乙酸共聚物微球用于眼内给药。包封技术、体外释放曲线及灭菌工艺。

Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration. Encapsulation technique, in vitro release profiles, and sterilization process.

作者信息

Herrero-Vanrell R, Ramirez L, Fernandez-Carballido A, Refojo M F

机构信息

Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA.

出版信息

Pharm Res. 2000 Oct;17(10):1323-8. doi: 10.1023/a:1026464124412.

Abstract

PURPOSE

The purpose of this work was to obtain a sterilized formulation consisting of biodegradable microspheres of poly (DL-lactide-co-glycolide) (PLGA) for intraocular sustained release of ganciclovir.

METHODS

Microspheres were prepared using a dispersion of ganciclovir in fluorosilicone oil (FSiO) that was further dispersed in an acetone solution of PLGA [50/50 and inherent viscosity 0.41 dl/g], and emulsified in silicone oil with a surfactant. Once prepared, the formulation was exposed with an effective gamma radiation dose of 2.5 megarads. The release rate data of ganciclovir from the sterilized and nonsterilized batches were compared using the similarity factor (f2).

RESULTS

The dispersion of the drug in FSiO contributed to achieving a drug payload of up to 95% of the theoretical in the 300-500 microm microspheres. Ten mg released ganciclovir in vitro at 1.3 microg/h for the first 21 days, but decreased to approximately 0.2 microg/h from day 25 until the end of the release study (42 days). No significant differences in the amounts of encapsulated drug (alpha = 0.05) were observed between the sterilized and nonsterilized microspheres. Furthermore, dissolution profiles of formulations behaved similarly before and after gamma radiation exposure.

CONCLUSIONS

The technique of microsphere preparation described resulted in high ganciclovir loading (95%) and prolonged drug release. The ganciclovir formulation behaved similarly before and after the sterilization process.

摘要

目的

本研究旨在制备一种由聚(DL-丙交酯-共-乙交酯)(PLGA)可生物降解微球组成的灭菌制剂,用于眼内持续释放更昔洛韦。

方法

将更昔洛韦分散于氟硅油(FSiO)中,再将其进一步分散于PLGA[50/50,特性粘度0.41 dl/g]的丙酮溶液中,加入表面活性剂在硅油中乳化制备微球。制备完成后,用2.5兆拉德的有效γ辐射剂量对制剂进行辐照。使用相似因子(f2)比较灭菌批次和未灭菌批次更昔洛韦的释放速率数据。

结果

药物在FSiO中的分散有助于在300 - 500微米的微球中实现高达理论载药量95%的载药量。10毫克更昔洛韦在体外前21天以1.3微克/小时的速率释放,但从第25天到释放研究结束(42天),释放速率降至约0.2微克/小时。灭菌微球和未灭菌微球之间的包封药量无显著差异(α = 0.05)。此外,γ辐射前后制剂的溶出曲线表现相似。

结论

所描述的微球制备技术导致了高更昔洛韦载药量(95%)和延长的药物释放。灭菌前后更昔洛韦制剂表现相似。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验